Literature DB >> 15697328

Intramuscular olanzapine: a review of its use in the management of acute agitation.

Antona J Wagstaff1, Jane Easton, Lesley J Scott.   

Abstract

Intramuscular olanzapine (Zyprexa) is a rapid-acting atypical antipsychotic drug that is also indicated for use in patients with agitation associated with schizophrenia or bipolar mania, the focus of this review. Evidence from three well designed trials indicates that this formulation of olanzapine is at least as effective as intramuscular haloperidol or lorazepam in the treatment of patients with acute agitation associated with schizophrenia or bipolar mania, and has a faster onset of action. Although transient reductions in blood pressure and heart rate may occur in some patients administered intramuscular olanzapine, preliminary evidence of a general lack of clinical effect on the corrected QT (QTc) interval and a low incidence of extrapyramidal symptoms (EPS) is promising. The parenteral formulation of olanzapine appears to offer an effective, fast-acting and generally well tolerated alternative in the treatment of this significant behavioural problem.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15697328     DOI: 10.2165/00023210-200519020-00005

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  42 in total

1.  Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Authors:  B R Basson; B J Kinon; C C Taylor; K A Szymanski; J A Gilmore; G D Tollefson
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

2.  5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.

Authors:  Vicki L Ellingrod; Paul J Perry; Brian C Lund; Kristy Bever-Stille; Frank Fleming; Timothy L Holman; Del Miller
Journal:  J Clin Psychopharmacol       Date:  2002-12       Impact factor: 3.153

Review 3.  Relationship of atypical antipsychotics with development of diabetes mellitus.

Authors:  Leslie L Citrome; Ari B Jaffe
Journal:  Ann Pharmacother       Date:  2003-12       Impact factor: 3.154

4.  The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.

Authors:  R C Smith; M Infante; A Singh; A Khandat
Journal:  Int J Neuropsychopharmacol       Date:  2001-09       Impact factor: 5.176

5.  Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.

Authors:  P Wright; M Birkett; S R David; K Meehan; I Ferchland; K J Alaka; J C Saunders; J Krueger; P Bradley; L San; M Bernardo; M Reinstein; A Breier
Journal:  Am J Psychiatry       Date:  2001-07       Impact factor: 18.112

6.  Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

Authors:  J Czekalla; C M Beasley; M A Dellva; P H Berg; S Grundy
Journal:  J Clin Psychiatry       Date:  2001-03       Impact factor: 4.384

Review 7.  The role of typical and atypical antipsychotic medications in the management of agitation and aggression.

Authors:  P F Buckley
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

Review 8.  Olanzapine: a review of its use in the management of bipolar I disorder.

Authors:  Paul L McCormack; Lynda R Wiseman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.

Authors:  Padraig Wright; Karena Meehan; Martin Birkett; Stacy R Lindborg; Cindy C Taylor; Philip Morris; Alan Breier
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

Review 10.  Torsade de pointes associated with the administration of intravenous haloperidol.

Authors:  Hesham A Hassaballa; Robert A Balk
Journal:  Am J Ther       Date:  2003 Jan-Feb       Impact factor: 2.688

View more
  7 in total

Review 1.  Olanzapine: in adolescents with schizophrenia or bipolar I disorder.

Authors:  Paul L McCormack
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 2.  Pharmacologic management of acutely agitated pediatric patients.

Authors:  Loretta Sonnier; Drew Barzman
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

Review 3.  Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

Review 4.  [Pharmacotherapy of psychiatric acute and emergency situations: General principles].

Authors:  T Messer; F-G Pajonk; M J Müller
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

5.  A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.

Authors:  Theodore D Satterthwaite; Daniel H Wolf; Robert A Rosenheck; Raquel E Gur; Stanley N Caroff
Journal:  J Clin Psychiatry       Date:  2008-12-02       Impact factor: 4.384

6.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

7.  Intramuscular Olanzapine - a UK case series of early cases.

Authors:  Chris J Bushe; Mark Taylor; Mathew Mathew
Journal:  Ann Gen Psychiatry       Date:  2007-04-01       Impact factor: 3.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.